CP-690,550 Phase II RA Results

Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690,550, an orally active Janus kinase (JAK)inhibitor: results from a randomized, double-blind, placebo-controlled trial.
Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH.

JNK - Pfizer

Pharmacological characterization of a small-molecule inhibitor of c-Jun kinase. Cho HK, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, Siegel K, McDonnell SR, Yu XH, Chen P, Yie J, Ogilvie KM, Fraser JD, Briscoe CP.

Selectivity Prediction - Pfizer

Predicting Kinase Selectivity Profiles Using Free-Wilson QSAR Analysis. Sciabola S, Stanton RV, Wittkopp S, Wildman S, Moshinsky D, Potluri S, Xi H.